Search

Background: Noncultured, extracted follicular outer root sheath suspension (NC-EHF-ORS-CS) is a recently introduced technique for the treatment of stable vitiligo., Objective: To study the clinical efficacy of this technique and to determine the viability and cell composition of the suspension., Methods: Twenty-five patients with stable vitiligo were included in this prospective study. Fifty follicles were extracted from occipital scalp and were incubated with trypsin-ethylenediaminetetraacetic acid to separate outer root sheath cells. The cell suspension was filtered and centrifuged to obtain a cell pellet, which was resuspended and applied to the dermabraded recipient area. Cell viability of the suspension was assessed using trypan blue staining, and markers of keratinocyte stem cells (CD200) and melanocytes (S100) were evaluated using flow cytometry and immunocytochemistry, respectively., Results: At 6 months, the mean (±SD) repigmentation was 52 ± 25.1%, and >75% repigmentation was seen in 8/25 (32%) patients. Mean percentage cell viability of the suspension was 80 ± 17.2% with a mean concentration of CD200 + and S100 + cells being 7.91 ± 8.68% and 9.93 ± 1.22% (n = 3), respectively. Recipient site infection was seen in 4 of 25 (16%) patients and a color mismatch in 11 of 25 (44%) patients., Conclusion: NC-EHF-ORS-CS is a useful minimally invasive therapy for vitiligo., (© 2017 The International Society of Dermatology.)

Background: Narrow‑band ultraviolet B (NB‑UVB) is the standard therapy for vitiligo. Objective: The objective of this study is to compare the safety and clinical efficacy of a handheld NB‑UVB comb device with the standard whole‑body NB‑UVB therapy in localized stable vitiligo. Materials and Methods: Thirty‑one vitiligo patients were allocated to either daily therapy with a home‑based handheld comb device (group A, n = 17) or thrice‑weekly hospital‑based whole‑body NB‑UVB therapy (group B, n = 14) for 4 months, based on their preference. The primary and secondary outcomes were assessed at each follow‑up, and appropriate statistical tools were used for analysis. Results: Of the 31 patients enrolled, 26 patients (study groups A/B: 15/11) completed the study. Primary outcome: Median percentage repigmentation of the representative patch in groups A and B were 51.35% and 63.85%, respectively (P = 0.64). The median size reduction of the representative patch in both groups was statistically significant (P < 0.05). The mean difference between “per protocol analysis” and “intention to treat” showed noninferiority. Secondary outcomes: Both groups were comparable on Lund and Browder score, patient global assessment and investigator global assessment scores, adverse events, color match, and change in the quality of life. The comparison group had a significantly greater number of missed sessions (P = 0.02). The majority of patients had a “good” response in both groups. Conclusion: Handheld NB‑UVB comb device daily with a fixed dose of fluence was found to be noninferior with better compliance to standard whole‑body NB‑UVB therapy [ABSTRACT FROM AUTHOR]

J Dermatol 2016;43:275-9. 2 Harb J, Motaparthi K. Clinicopathologic findings of guttate leukoderma in Darier disease: A helpful diagnostic feature. Thus, dermoscopic evaluation of greasy papules and guttate leukoderma may allow earlier diagnosis of this disease and may help in appropriate management. A 15-year-old boy presented with multiple itchy hyperpigmented papules over face and trunk and hypopigmented macules over limbs for the last 8 years. [Extracted from the article]